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1 Drug description 
Generic/Brand name/ATC code:  
Bevacizumab/(Avastin®) / L01X C07  
Developer/Company:  
Roche Pharma AG  
Description:  
Bevacizumab, the active substance of Avastin® is a recombinant humanized 
monoclonal IgG1 antibody [1]. It binds to the vascular endothelial growth 
factor (VEGF), the key driver of vasculogenesis and angiogenesis, and there-
by inhibits the binding of VEGF to its receptors, VEGFR-1 and VEGFR-2, 
on the surface of endothelial cells. Neutralizing the biological activity of 
VEGF regresses the vascularization of tumours, normalizes remaining tu-
mour vasculature, and inhibits the formation of new tumour vasculature, 
thereby inhibiting tumour growth [2, 3].  
Avastin® is available in 4 ml or 16 ml vials containing 25mg/ml bevacizu-
mab. It is administered by intravenous infusion and must be diluted before 
use. The recommended dosing regimen for the treatment of metastatic 
breast cancer (BC) is 10 mg/kg body weight given once every 2 weeks or 15 
mg/kg body weight given once every 3 weeks [1, 2].  
Adverse events (AEs) associated with bevacizumab treatment may be gastro-
intestinal perforations, fistulae, wound healing complications, hypertension, 
proteinuria, arterial and venous thromboembolism, haemorrhage, pulmo-
nary haemorrhage/haemoptysis, congestive heart failure, reversible posterior 
leucoencephalopathy syndrome and neutropenia [2, 3]. 
2 Indication 
Bevacizumab (Avastin®) in combination with chemotherapy regimens for 
the treatment of patients with previously treated metastatic BC that is as 2nd 
or late-line therapy.  
bevacizumab inhibits 
the binding of VEGF to 
its receptors 
intravenous infusion 
recommended dosing 
regimen for metastatic 
breast cancer (BC)… 
as second-line therapy 
for metastatic BC 
Horizon Scanning in Oncology 
4 LBI-HTA | 2012 
3 Current regulatory status 
The European Medicines Agency (EMA) [2] approved Avastin® for the use 
in the European Union,  
 in combination with paclitaxel for first-line treatment of patients with 
metastatic BC [2, 4].  
 in combination with capecitabine for first-line treatment of patients 
with metastatic BC in whom treatment with other chemotherapy op-
tions including taxanes or anthracyclines is not considered appropri-
ate. Patients who have received taxanes and anthracycline-containing 
regimens in the adjuvant setting within the last 12 months should be 
excluded from treatment with Avastin® in combination with capecit-
abine. 
 in combination with fluoropyrimidine-based chemotherapy for treat-
ment of patients with metastatic carcinoma of the colon or rectum. 
 in addition to platinum-based chemotherapy for first-line treatment 
of patients with unresectable advanced, metastatic or recurrent non-
small cell lung cancer other than predominantly squamous cell histol-
ogy. 
 in combination with interferon alfa-2a for first-line treatment of pa-
tients with advanced and/or metastatic renal cell cancer. 
 in combination with carboplatin and paclitaxel for the front-line 
treatment of advanced epithelial ovarian, fallopian tube, or primary 
peritoneal cancer. 
In November 2011 the U.S. Food and Drug Administration (FDA) withdrew 
the approval for Avastin® in combination with paclitaxel for treatment of pa-
tients who have not received chemotherapy for metastatic human epidermal 
growth factor receptor 2 (HER2)-negative BC. This decision was based on 
the results of 2 trials (AVADO [5] and RIBBON-1 [6]), where bevacizumab 
has not been shown to provide a benefit, in terms of delay in the growth of 
tumours, that would justify its serious and potentially life-threatening risks. 
There is also no evidence that the use of bevacizumab will either help wom-
en with BC to live longer or to improve their quality of life (QoL) [7]. 
Avastin® remains on the U.S. market as an approved treatment for [1], 
 metastatic colorectal cancer, with intravenous 5-fluorouracil–based 
chemotherapy for first- or second-line treatment. 
 non-squamous non-small cell lung cancer, with carboplatin and pacli-
taxel for first-line treatment of unresectable, locally advanced, recur-
rent or metastatic disease. 
 glioblastoma, as a single agent for adult patients with progressive dis-
ease following prior therapy. 
 metastatic renal cell carcinoma with interferon alfa. 
EMA: approved for first-
line therapy of BC, but 
not for second-line 
recommended only with 
paclitaxel as first-line 
therapy for metastatic 
BC  
for metastatic 
carcinoma of colon or 
rectum, non-small cell 
lung cancer, renal cell 
cancer,  advanced 
epithelial ovarian, 
fallopian tube, or 
primary peritoneal 
cancer 
FDA: 
withdrew the approval 
for first-line therapy of 
patients with metastatic 
HER2-negative BC 
for metastatic colorectal 
cancer, non-squamous 
non-small cell lung 
cancer, glioblastoma or 
metastatic renal cell 
carcinoma 
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4 Burden of disease 
In 2009, about 5,000 women were newly diagnosed with BC [8] and 1,500 
died from BC in Austria [9]. Thus, with a percentage of 28.5%, BC is the 
most common type of cancer in females [10]. Between 2005 and 2007 the ma-
jority of malignant neoplasm of the breast were diagnosed in women aged 45 
to 85 years [11]. The age standardized (per 100,000 population, defined by 
WHO 2001) incidence rate for BC in women dropped from 75.0 (1998) to 
69.4 (2009) in Austria. In the same period, the age standardized death rate 
declined from 21.6 (1998) to 17.3 (2009) [8, 9, 11]. Several well-established 
factors have been associated with an increased risk of BC, including age, 
positive family history, nulliparity, early menarche a personal history of BC 
and genetic factors [12]. 
The American Joint Committee on Cancer has designated a staging by Tu-
mour Node Metastasis (TNM) classification to define BC. The TNM pro-
vides a strategy for grouping patients with respect to prognosis. Besides the 
staging of the primary tumour, the extent to which regional lymph nodes are 
involved and the absence or presence of distant metastases are taken into ac-
count, leading to four main stage groupings (stage T1 to T4) where metas-
tatic disease is coded as stage T4 [13, 14]. Metastases are most common in 
the bones, liver or the lungs. In 2007, the British Secondary Breast Cancer 
Taskforce reported that about 5% of women and men diagnosed with BC be-
tween 1992 and 1994 had metastases at the time of their primary diagnosis 
and a further 35% of all those with a primary diagnosis went on to develop 
metastases within the following 10 years [15]. In Austria, 5.2% of female pa-
tients with initially diagnosed BC had disseminated disease [16]. The prog-
nosis for metastatic BC is generally poor and the 15-year cause-specific sur-
vival rates range between 7% and 8.3% [17]. The median overall survival 
(OS) approaches two years, with a range from a few months to many years, 
with patients with either HER2-overexpression or triple-negative (oestrogen 
receptor, progesterone receptor, HER2) metastatic BC having an even short-
er survival [18]. 
Prognostic factors for metastatic disease include the length of the relapse-
free interval after the initial treatment, the number of metastases, locations 
involved (worse prognosis with hepatic, lymphangitic pulmonary metasta-
ses, bone marrow replacement, carcinomatous meningitis) and biological 
markers (e.g., good prognosis is associated with hormone receptor positive 
state). Additionally, weight loss, poor performance status and age less than 
35 years in woman with early stage BC have an unfavourable prognosis [18]. 
Biological markers for prognosis as well as for therapeutic decisions include 
oestrogen receptor, progesterone receptor and HER2-status [19]. 
5 Current treatment 
The treatment of BC includes the treatment of local disease with surgery, 
radiation therapy, or both, and the treatment of systemic disease with cyto-
toxic chemotherapy, endocrine therapy, biologic therapy or combinations of 
these. The choice of therapy is based on a number of prognostic and predic-
BC is most common 
type of cancer in women  
 
 
risk factors 
TNM staging 
classification 
 
 
 
 
 
in Austria 5.2% of 
women have 
disseminated disease at 
diagnoses 
prognostic factors for 
metastatic BC 
 
status of oestrogen-, 
progesterone receptor 
and HER2 are 
biomarkers for 
therapeutic decisions 
treatment of local 
disease and treatment 
of systemic disease 
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tive factors like tumour histology, characteristics of the primary tumour, ax-
illary node status, tumour hormone receptor content, HER2- status, pres-
ence of detectable metastatic disease, comorbid conditions, age, and meno-
pausal status [20]. 
The management of patients with advanced BC is complex. When making 
treatment choices there is a trade-off between QoL, the risks of toxicity and 
the likelihood of benefit in terms of improving symptoms, QoL or survival 
[15]. Details of the treatment of advanced BC have been described in a re-
cent Horizon Scanning Document on lapatinib [21]. 
For metastatic BC the therapy is palliative in intent. Goals of treatment in-
clude improving QoL and prolongation of life. The treatment of metastatic 
BC is influenced by many factors and should be tailored individually. Ulti-
mately, the choice of therapy should be based on patient preferences. Clini-
cal advice will take into account the presence or absence of comorbidities, 
treatment effectiveness, performance status, the site and extent of disease, 
the presence or absence of symptoms, and the rate at which the disease ap-
pears to be progressing [15]. 
Primary strategy for the treatment of metastatic BC is the administration of 
systemic therapy that can be divided into three categories– endocrine ther-
apy, chemotherapy and biological therapy [20]. Radiation therapy or surgery 
may be indicated for patients with limited symptomatic metastases [22]. 
 endocrine therapy 
Endocrine therapy (e.g. anastrazole, tamoxifen, letrozole or fulvestrant) is 
appropriate for approximately 70% of patients who have hormone receptor 
positive advanced BC [15]. Hormone therapy is especially indicated if the 
patient’s disease involves only bone and soft tissue metastases and the pa-
tient has either not received adjuvant antioestrogen therapy or has been off 
such therapy for more than 1 year [22]. It is not used in combination with 
chemotherapy but is combined in certain circumstances with biological 
therapy, although high-quality evidence is lacking [15]. 
 chemotherapy  
Chemotherapy is used in the treatment of both hormone receptor positive 
and negative patients with metastatic BC [15]. Patients whose tumours have 
progressed on hormone therapy or patients with visceral metastases are also 
candidates for chemotherapy [22]. A number of different chemotherapy 
drugs, or classes of drug, are used, including anthracyclines, taxanes, cape-
citabine, vinorelbine, gemcitabine, alkylating agents and platinum-based 
drugs [15]. Whether single-agent chemotherapy or combination chemother-
apy is preferable for first-line treatment is unclear [22]. 
 biological therapy 
Over the last 10 to 15 years the identification of some of the molecular proc-
esses occurring in BC has led to the development of new treatment options 
using agents which can be directed specifically at these molecular processes. 
They may be used alone or in combination with chemotherapy or endocrine 
therapy. There are currently three main biological therapies used in patients 
with advanced BC – trastuzumab for patients whose tumours have either 
HER2-overexpression or HER2-gene amplification, lapatinib for patients 
who have HER2-positive metastatic BC that progressed after treatment with 
for advanced BC: 
complex management 
palliative intent 
endocrine therapy: 
anastrazole 
tamoxifen 
letrozole 
fulvestrant 
chemotherapy: 
taxanes 
capecitabine 
vinorelbine 
gemcitabine 
biological therapy: 
trastuzumab 
lapatinib 
bevacizumab 
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trastuzumab, and bevacizumab. [15, 22]. According to the National Institute 
of Clinical Excellence (NICE), trastuzumab is currently the only one of the-
se agents recommended for use in patients with advanced BC, in combina-
tion with chemotherapy [15].  
 surgery  
Surgery may be indicated for selected patients. Examples include patients 
who need mastectomies for fungating (marked by ulcerations and necrosis) 
/painful breast lesions, parenchymal brain or vertebral metastases with spi-
nal cord compression or isolated lung metastases [22]. 
 radiation therapy  
Radiation therapy has a major role in the palliation of localized sympto-
matic metastases. Indications include painful bony metastases, unresectable 
central nervous system metastases, bronchial obstruction, and fungat-
ing/painful breast or chest wall lesions. Radiation therapy is also used after 
surgery for decompression of intracranial or spinal cord metastases and fol-
lowing fixation of pathologic fractures [22]. 
6 Evidence 
A systematic literature search in medical databases (Medline/Pubmed, Em-
base, Cochrane databases, CRD) in addition to a hand search resulted after 
removal of duplicates in 216 records overall. Of those, 11 records reporting 
results of 2 phase III trials and 6 single arm phase II trials, were included 
[23-33]. 
6.1 Efficacy and safety - Phase III studies 
 
Table 1: Summary of efficacy (Ribbon-2) 
Study title A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemo-
therapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) [23] 
Study  
identifier 
NCT00281697; EudraCT Number: 2006-006507-36 
Randomised (2:1 ratio), double-blind, placebo-controlled international, multi-centre trial;  
N = 684 (225 vs. 459); 
allocation randomly to chemotherapy (capecitabine-,gemcitabine-, vinorelbine-, or taxane-
based) + bevacizumab (BV) or chemotherapy + placebo; stratification on the interval from 
metastatic BC diagnosis to first PD, investigator choice of chemotherapy, and estrogen re-
ceptor or progesterone receptor status. 
ITT-Analysis 
Design 
Duration  Enrolment: February 2006 to June 2008 
Median follow-up: 15 months 
Cut-off date for final analysis: March 31, 2009 
surgery  
radiation therapy  
2 phase III trials 
6 single arm phase II 
trials 
Horizon Scanning in Oncology 
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Hypothesis Superiority 
Funding Genentech, South San Francisco, CA. 
Intervention Chemotherapy + BV: 
Chemotherapy on investigators choice: 
 capecitabine 1,000 mg/m2 orally twice per day on 
days 1 through 14 every 3 weeks; 
 docetaxel 75 to 100 mg/m2 iv every 3 weeks; nab-
paclitaxel 260 mg/m2 iv every 3 weeks; 
 paclitaxel 90 mg/m2 iv on days 1, 8, and 15 every 4 
weeks or 175 mg/m2 iv every 3 weeks; 
 gemcitabine 1,250 mg/m2 iv on days 1 and 8 every 3 
weeks; or vinorelbine 30 mg/m2 iv every 3 weeks 
Chemotherapy was continued until PD, unacceptable toxicity, 
investigator decision, or death. Doses could be modified at in-
vestigator discretion. 
BV: 10 or 15 mg/kg iv every 2 or 3 weeks, respectively, depend-
ing on the chemotherapy regimen; 
BV was continued until PD, unacceptable toxicity, investigator 
decision, completion of 36 months of BV, or death; BV could 
continue as monotherapy, if chemotherapy was discontinued 
before PD. 
Treatment 
groups 
Control Chemotherapy + placebo: 
Chemotherapy on investigators choice: 
 capecitabine 1,000 mg/m2 orally twice per day on 
days 1 through 14 every 3 weeks; 
 docetaxel 75 to 100 mg/m2 iv every 3 weeks; nab-
paclitaxel 260 mg/m2 iv every 3 weeks; 
 paclitaxel 90 mg/m2 iv on days 1, 8, and 15 every 4 
weeks or 175 mg/m2 iv every 3 weeks; 
 gemcitabine 1,250 mg/m2 iv on days 1 and 8 every 3 
weeks; or vinorelbine 30 mg/m2 iv every 3 weeks 
Chemotherapy was continued until PD, unacceptable toxicity, 
investigator decision, or death. Doses could be modified at in-
vestigator discretion. 
Placebo: placebo could continue as monotherapy, if chemo-
therapy was discontinued before PD. 
Progression-free survival 
(primary efficacy end point) 
PFS Time from random assignment to first PD or 
death as a result of any cause. 
Objective response rate (sec-
ondary endpoint) 
ORR Percentage of patients with measurable dis-
ease who achieved a CR or PR confirmed ≥ 28 
days after initial documentation of response
(according to RECIST version 1.0). 
overall survival (secondary 
endpoint) 
OS Time from random assignment until death. 
Progression-free survival 
within individual chemo-
therapy regimen (secondary 
endpoint) 
PFS ind Time from random assignment to first PD or 
death as a result of any cause. 
Endpoints 
and defini-
tions 
1-year survival rate (secon-
dary endpoint) 
1ySR Percentage of patients who were alive 1 year 
after randomisation 
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Safety (secondary endpoint) S AEs leading to study drug discontinuation, 
SAEs, and selected AEs previously associated 
with BV or chemotherapy 
Results and analysis 
Analysis  
description 
Primary analysis: 
The intent-to-treat (ITT) population was the primary efficacy analysis population. It was 
pooled over all the chemotherapy cohorts and performed at the two-sided α = .05 level. 
Time-to-event variables were compared between treatment arms by using a stratified log-
rank test, and the duration of time-to-event data was estimated by using the Kaplan-Meier 
method. The 95% CIs for median time to event were computed by using the Brookmeyer-
Crowley method. Hazard Ratios (HRs) for time-to-event variables were estimated by using a 
stratified Cox regression model.  
Characteristics 684 patients with histologically confirmed, locally recurrent 
breast cancer or metastatic BC who had received one prior cy-
totoxic treatment for metastatic BC 
Control vs. Intervention: 
Median age (years): 55 vs. 55  
ECOG performance status 1: 51% vs 50% 
HER2-negative: 85% vs. 84% 
HER2-status unknown: 14% vs. 15% 
≥ 3 metastatic sites: 47% vs. 44% 
Visceral disease: 71% vs. 74% 
Hormone receptor positive disease: 73% vs 72% 
Triple-negative disease: 21% vs. 24% 
Inclusion Age ≥ 18 years; histologically confirmed, locally recurrent or 
metastatic BC; one prior cytotoxic treatment for metastatic 
BC; ECOG performance status of 0 or 1. 
Analysis  
population 
Exclusion HER2–positive status; prior BV or other VEGF pathway–
targeted therapy; untreated brain metastases; unstable an-
gina; congestive heart failure (> Class II); history of myocar-
dial infarction, stroke, or transient ischemic attack within the 
last 6 months; clinically significant peripheral vascular disease; 
bleeding diathesis or coagulopathy; history of abdominal fis-
tula, GI perforation, or intraabdominal abscess within the last 
6 months; serious non-healing wound; or inadequate organ 
function. 
Treatment group Chemotherapy 
+ placebo 
Chemotherapy + BV 
Number of subjects 225 459 
PFS (months) 
median 
95% CI 
 
5.1 
4.1 – 6.0 
 
7.2 
6.5 – 7.6 
OS (months) 
median 
95% CI 
 
16.4 
14.6 – 20.2 
 
18.0 
17.1 – 20.2 
1ySR (%) 
median 
95% CI 
 
66.2 
59.7 – 72.8 
 
69.5 
65.0 – 74.0 
Results 
Number of subjects 179 362 
Horizon Scanning in Oncology 
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ORR (%) 
 CR (%) 
 PR (%) 
29.6 
1.1 
28.5 
39.5 
2.2 
37.3 
Comparison groups  Intervention vs Control 
HR 0.78 
95% CI 0.64 – 0.93 
PFS 
P value  0.0072 
HR 0.90 
95% CI 0.71 – 1.14 
OS 
P value  0.3741 
Point estimate NR 
Variability NR 
Effect es-
timate per 
comparison 
ORR 
P value  0.0193 
AE ... adverse event; BC ... breast cancer; BV ... bevacizumab; CI ... confidence interval; CR ... complete response; 
ECOG ... Eastern Cooperative Oncology Group; HER2 ... human epidermal growth factor receptor 2; 
HR ... hazard ratio; ITT ... intention-to-treat; iv ... intravenous ; NR ... not reported; ORR ... objective re-
sponse rate; OS ... overall survival; PD ... disease progression; PFS ... progression-free survival; PR ... partial 
response; RECIST ... Response Evaluation Criteria in Solid Tumours; SAE ... serious adverse event; 
VEGF ... vascular endothelial growth factor. 
 
Table 2: Most frequent adverse events (RIBBON-2) 
Grade (according 
to NCI CTC AE ver-
sion 4.0) 
Outcome  Chemotherapy + BV 
(n= 458) 
Chemotherapy + 
placebo (n= 221) 
SAE 112 (24.5%) 39 (17.6%) All Grades 
AE leading to discontinuation 61 (13.3%) 16 (7.2%) 
AE previously shown to be asso-
ciated with BV or chemotherapy 
161 (35.2%) 50 (22.6%) 
AE leading to death 6 (1.3%) 5 (2.3%) 
Neutropenia 81 (17.7%) 32 (14.5%) 
Hypertension 41 (9.0%) 1 (0.5%) 
Sensory neuropathy 29 (6.3%) 13 (5.9%) 
Proteinuria 14 (3.1%) 1 (0.5%) 
Febrile neutropenia 10 (2.2%) 6 (2.7%) 
Bleeding events 8 (1.7%) 0 (0.0%) 
Left ventricular systolic dysfunc-
tion 
4 (0.9%) 0 (0.0%) 
ATE 3 (0.7%) 3 (1.4%) 
Wound dehiscence 1 0 
GI perforation  2 (0.4%) 0 (0.0%) 
Grade ≥3 
RPLS 0 (0.0%) 0 (0.0%) 
AE ... adverse event; ATE ... arterial thromboembolic event; BV ... bevacizumab; GI ... gastrointestinal; 
RPLS ... reversible posterior leukoencephalopathy syndrome; SAE ... serious adverse event. 
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The Ribbon-2 trial [23, 31, 32] was an international, multi-centre, double-
blind, placebo-controlled randomised trial (RCT) with study centres in the 
European Union, USA and various other countries. The aim of the study was 
to evaluate the efficacy and safety of bevacizumab in combination with 
chemotherapies for second-line therapy of HER2-negativ metastatic BC. 684 
patients aged 18 years or older with metastatic HER2-negativ BC, who had 
received one prior cytotoxic treatment for metastatic BC, were included. 459 
of them were allocated to chemotherapy + bevacizumab, while 225 received 
chemotherapy + placebo. Chemotherapy regimen was given on investigators 
choice. The median number of doses of the study drug (placebo or bevaci-
zumab) received was 6 for the chemotherapy + placebo arm and 9 for the 
chemotherapy + bevacizumab arm, with a median duration of treatment of 
4 and 6 months, respectively. The median duration of chemotherapy expo-
sure was higher in the chemotherapy + bevacizumab arm by 1 month com-
pared with the chemotherapy + placebo arm for all cohorts except vinorel-
bine. 
At the end of the data cut-off, chemotherapy + bevacizumab resulted in a 
statistically significant reduction in the risk of a disease progression (PD) or 
death of 22% (HR = 0.78; 95% CI: 0.64 - 0.93; p = 0.0072) and in a 2.1 
months improvement in median progression-free survival (PFS) (7.2 vs. 5.1 
months). In a predefined subgroup analysis according to different chemo-
therapy regimens (taxane 304 patients; gemcitabine 160 patients; capecit-
abine 144 patients; vinorelbine 76 patients), the PFS in favour of the inter-
vention remained significant only for the taxane combination (HR = 0.64; 
95% CI: 0.49 - 0.84). For the vinorelbine combination there was even a ten-
dency towards longer PFS in the control group (HR = 1.42; 95% CI: 0.78 - 
2.59). 
A subgroup analysis for patients with triple negative metastatic BC (TNBC) 
(23% of all patients) showed a median improvement in PFS of 3.3 months 
(HR = 0.494; 95% CI: 0.33-0.74; p=0.0006). 
The secondary end point, objective response rate (ORR) was about 10% 
higher in the bevacizumab group compared to placebo (37.2% vs. 28.5%), 
which was statistically not significant (p= 0.0193, prespecified α of 0.01). 
The ORR for the TNBC subgroup was 41% vs. 18% in favour of the bevaci-
zumab group, which was statistically significant (p = 0.0078) [31]. In all 
analyses the overwhelming majority of confirmed responses in both cohorts 
were partial responses. 
For the overall survival (OS) only interim results are reported so far. There 
were no statistically significant differences in the interim OS (HR = 0.90; 
95% CI: 0.71 – 1.14; p = 0.3741) and in the 1-year survival rate (69.5% vs. 
66.2%) for either the whole population or the TNBC subgroup (OS: HR = 
0.624; 95% CI: 0.39 – 1.007; p = 0.0534; 1ySR: 63% vs. 50%). The number of 
deaths were 206 (44.9%) vs. 109 (48.4%) for the whole population and 52 
(46%) vs. 29 (62%) for the TNBC subgroup. 
Selected grade ≥ 3 adverse events (AEs), previously shown to be associated 
with bevacizumab or chemotherapy (e.g. hypertension, bleeding, proteinu-
ria), as well as serious adverse events (SAEs) were more often observed in 
the bevacizumab group than in the placebo group (35.4% vs. 22.6%; 24.5% 
vs. 17.6%). Neutropenia (17.7% vs. 14.5%), sensory neuropathy (6.3% vs. 
5.9%) and hypertension (9.0% vs. 0.5%) were the most common grade ≥ 3 
AEs. AEs that led to a study discontinuation occurred almost twice as fre-
quently in the bevacizumab group than in the placebo group (13.3% vs. 
double-blind, placebo-
controlled RCT 
bevacizumab + 
chemotherapy for 
second-line therapy of 
metastatic HER2-
negativ BC 
significant reduction of 
risk for PD or death 
 
subgroup analysis: 
significant only for 
taxane + bevacizumab 
significant for triple 
negative BC 
no difference between 
chemotherapy + 
bevacizumab and  
chemotherapy + 
placebo in ORR, OS and 
1-year survival rate  
OS in interim results no 
statistically significant 
differences 
most common AEs: 
neutropenia, sensory 
neuropathy and 
hypertension 
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7.2%). There was no difference in the number of treatment-related deaths as 
a result of AEs between the two groups (1.3% vs. 2.3%). 
Based on these results the authors concluded that bevacizumab in combina-
tion with chemotherapy should be considered as second-line therapy for pa-
tients with HER2-negative metastatic BC. 
 
Table 3: Summary of efficacy (Miller 2005) 
Study title: Randomised phase III trial of capecitabine compared with bevacizumab plus capecitabine in 
patients with previously treated metastatic breast cancer [24, 33] 
Study  
identifier 
ClinicalTrial.gov: NCT00109239, NCT00012285 (obsolete);   
GENENTECH-AVF2119g 
Randomised (1:1 ratio), two-arm open-label multi-centre (96) study; N=462  
allocation randomly to 2 treatment groups (230 capecitabine alone, 232 combination 
treatment); stratification on study site, ECOG performance status (0 or 1) and number 
of prior chemotherapy regimens for metastatic disease (0 or ≥1) 
ITT analysis 
Design 
Duration  Enrolment: November 2000 to March 2002 
Median follow-up: NR 
Cut-off date for final analysis: 28 June 2002 (assessment of 
pharmacokinetics) 
Hypothesis Superiority of progression-free survival (PFS) 
Funding Genentech Inc, South San Francisco, CA 
Intervention Capecitabine (CAP) + bevacizumab (BV) 
CAP like in the control arm . 
BV (15 mg/kg) intravenously during 30-90 minutes on day 1 of each 
3-week cycle. Treatment was interrupted in case of proteinuria 
≥ 2,000 mg/24h until its resolution, but it was not discontinued for 
CAP-related toxicities. 
Treatment 
groups 
Control CAP monotherapy (CAP alone)  
CAP 2,500 mg/m2/d, orally twice daily for 14 days followed by a 7-
day rest period, administered for a maximum of 35 3-week cycles or 
until disease progression or unacceptable toxicity. 
If toxicity occurred and depending on its grade (according to NCI-
CTC), CAP was discontinued or interrupted and resumed at a 
reduced dose. 
Endpoints and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS defined as time from randomisation to the date of disease 
progression or death as determined by the independent 
review facility (primary end point) or by the investigators 
(secondary end point), whichever occurred first. 
Patients without an event were treated as censored at the 
time of the last tumour assessment. Tumour assessments 
more than 42 days after discontinuation of CAP were 
censored. 
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Objective response 
rate 
(secondary 
endpoint) 
ORR Objective response and disease progression were determined 
using the Response Evaluation Criteria in Solid Tumors 
(RECIST version 1.0) with minor modifications (i.e. a diameter 
of at least 2 cm was required to be assessed as a target lesion 
or an unequivocal progression of a nontarget lesion). 
To be considered an objective response, all CRs and PRs were 
to be confirmed at least 4 weeks after the initial response 
assessment. 
Tumour response was assessed every 6 weeks until 24 weeks, 
and then every 9 weeks. 
Duration of 
response 
(secondary 
endpoint) 
DoR Defined as duration of objective response. 
Quality of Life 
(secondary 
endpoint) 
TDQ Time to deterioration in Quality of Life (QoL). 
Measured every 6 weeks until 24 weeks, and then every 9 
weeks by the Trial Outcome Index (TOI) which is the sum of 
the physical well-being, functional well-being, and breast 
cancer–specific questions in the FACT-B questionnaire 
Version 4. 
A decline in TOI of more than five points from baseline, a 
disease progression, or death were considered a clinically 
meaningful deterioration in QoL. 
 Duration of 
Survival 
(secondary 
endpoint) 
DoS Duration of survival was defined as the time from 
randomisation to death. 
All patients were monitored for survival every 4 months. 
Results and analysis 
Analysis  
description 
Primary analysis:   
PFS for the BV + CAP group compared with the CAP-alone group, determined with a 
two-sided stratified log-rank test performed at the 0.0498 level (type I error of 0.01%).
An estimate of the hazard ratio with 95% CIs was determined using a stratified Cox 
regression model with an indicator variable for treatment group. Median PFS in each 
treatment group was estimated using the Kaplan-Meier method.   
All randomly assigned patients were included in the efficacy (ITT) analysis. 
Analysis  
population 
Characteristics 462 women with confirmed metastatic BC 
Control(n=230) vs. Intervention(n=232): 
Mean age (years): 52 vs. 51  
Ethnicity: Black / White (%): 10.9 / 80.4 vs. 12.9 / 80.6  
ECOG performance status 0 / 1 / 2 (%):  
 50 / 50 / 0 vs. 50.4 / 49.1 / 0.4  
Hormone Receptor Status: 
   Oestrogen receptor–positive (%): 51.7 vs. 41.8  
   Progesterone receptor–positive (%): 41.7 vs. 32.3  
HER2-positive (%): 20.4 vs. 26.3 
Median duration of metastatic disease (years): 1.3 vs. 1.0   
Visceral disease (%): 80.0 vs. 77.6  
≥ 3 sites of disease (%): 50.4 vs. 49.1 
Prior chemotherapy regimens for  
metastatic BC  0 / 1 / 2 / 3-5 (%):  
 16.1 / 42.6 / 37.8 / 3.5 vs. 15.1 / 46.1 / 34.1 / 4.7 
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Inclusion Women ≥ 18 years of age ;  
histologically or cytologically confirmed metastatic BC; prior 
therapy with both an anthracycline and a taxane; at least one, but 
no more than two, prior chemotherapy regimens for metastatic 
disease, or no intervening chemotherapy, if relapse occurred within 
12 months of completing adjuvant anthracycline and taxane 
therapy; progression following trastuzumab in case of HER2-
positive disease (3+ protein expression by immunohistochemistry or 
gene amplification by fluorescence in situ hybridization); 
bidimensionally measurable disease with at least one lesion 
measuring ≥ 2 cm; ECOG performance status of 0 or 1; adequate 
renal, hepatic, and hematologic function. 
Exclusion History or radiographic evidence of central nervous system disease 
(screening head computed tomography or brain magnetic resonance 
image required); other primary malignancy (except basal cell 
carcinoma of the skin or in situ cervical cancer within 5 years); 
major surgery within 4 weeks; other antitumour therapy within 21 
days; nonhealing wound or fracture, infection requiring parenteral 
antibiotics, or clinically significant cardiovascular disease; 
therapeutic anticoagulation (prophylactic anticoagulants to 
maintain a vascular access device permitted), regular nonsteroidal 
anti-inflammatory medication or aspirin (> 325 mg/d); 
administration of bisphosphonates initiated within 21 days before 
study entry 
Treatment group Control (CAP alone) Intervention (CAP + BV) 
Number of subjects 230 232 
PFS (months) 
median 
95%CI 
 
4.17 
NR 
 
4.86 
NR 
ORR (%) 
95% CI 
9.1% 
5.4% - 12.9% 
19.8% 
14.7% - 25.0% 
DoR (months) 
 median 
95% CI 
 
7.6 
NR 
 
5.0 
NR 
DoS* (months) 
 median 
95%CI 
*at data cutoff 
38% of all patients 
had died 
 
14.5 
NR 
 
15.1 
NR 
Number of subjects 176 194 
Results 
TDQ (months) 
 median 
95%CI 
 
2.86 
NR 
 
2.92 
NR 
Comparison groups  Intervention vs Control 
HR 0.98 
95% CI 0.77 - 1.25 
Effect estimate 
per comparison 
PFS 
P value  0.857 
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Point estimate NR 
Variability NR 
ORR  
P value  0.001 
Point estimate NR 
Variability NR 
DoR 
P value  similar 
Point estimate NR 
Variability NR 
DoS 
P value  similar 
Point estimate NR 
Variability NR 
TDQ 
P value  0.633 
BV ... Bevacizumab; CAP ... Capecitabine; CI ... Confidence interval; DoR ... Duration of response; DoS ... Duration 
of survival; ECOG ... Eastern Cooperative Oncology Group; FACT-B ... Functional Assessment Of Cancer 
Treatment—Breast; HER2 ... Human epidermal growth factor receptor 2; ITT ... Intent-to-treat; NCI-
CTC ... National Cancer Institute Common Toxicity Criteria; NR ... Not reported; ORR ... Objective 
response rate; PFS ... Progression-free survival; QoL ... Quality of Life; RECIST ... Response Evaluation 
Criteria in Solid Tumors; TDQ ... Time to deterioration in Quality of Life; TOI ... Trial Outcome Index 
 
Table 4: Most frequent adverse events (Miller 2005) 
Grade 
(according to 
NCI CTC AE 
version 2.0) 
Outcome  Intervention  
(CAP + BV) 
(n= 229) 
Control  
(CAP alone) 
(n= 215) 
Common BV Toxicities   
Proteinuria 42 (18.3%) 14 (6.5%) 
Grade 1 
only AEs>15% 
in one arm 
Bleeding 60 (26.2%) 19 (8.8%) 
Common CAP Toxicities   
Diarrhoea 37 (16.2%) 34 (15.8%) 
Hand-foot syndrome 97 (42.4%) 77 (35.8%) 
Other Common Toxicities   
Miscellaneous   
Asthenia 58 (25.3%) 35 (16.3%) 
Headache 26 (11.4%) 9 (4.2%) 
Grade 2 
only AEs>15% 
in one arm 
Pain 24 (10.5%) 20 (9.3%) 
Common CAP Toxicities   
Diarrhoea 27 (11.8%) 23 (10.7%) 
Stomatitis 4 (1.7%) 0 (0%) 
Hand-foot syndrome 63 (27.5%) 52 (24.2%) 
Common BV Toxicities   
Grade 3 
Hypertension 41 (17.9%) 1 (0.5%) 
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Proteinuria 2 (0.9%) 0 (0%) 
Bleeding 1 (0.4%) 1 (0.5%) 
Thrombotic event 9 (3.9%) 5 (2.3%) 
Pulmonary embolism 0 (0%) 0 (0%) 
Other Common Toxicities   
Hematologic   
Anaemia 4 (1.7%) 1 (0.5%) 
Leukopenia 6 (2.6%) 3 (1.4%) 
Thrombocytopenia 3 (1.3%) 1 (0.5%) 
Gastrointestinal   
Nausea 6 (2.6%) 4 (1.9%) 
Anorexia 2 (0.9%) 5 (2.3%) 
Constipation 1 (0.4%) 0 (0%) 
Cardiac   
Congestive heart failure 5 (2.2%) 0 (0%) 
Cardiomyopathy 1 (0.4%) 0 (0%) 
Infectious   
Infection 2 (0.9%) 1 (0.5%) 
Fever 1 (0.4%) 2 (0.9%) 
Miscellaneous   
Asthenia 14 (6.1%) 10 (4.7%) 
Headache 4 (1.7%) 1 (0.5%) 
Pain 7 (3.1%) 4 (1.9%) 
Common CAP Toxicities   
Diarrhoea 0 (0%) 0 (0%) 
Stomatitis 0 (0%) 1 (0.5%) 
Hand-foot syndrome 0 (0%) 0 (0%) 
Common BV Toxicities   
Hypertension, Proteinuria 0 (0%) 0 (0%) 
Bleeding 0 (0%) 0 (0%) 
Thrombotic event 4 (1.7%) 3 (1.4%) 
Pulmonary embolism 3 (1.3%) 3 (1.4%) 
Other Common Toxicities   
Hematologic   
Grade 4 
Anaemia 0 (0%) 0 (0%) 
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Leukopenia 0 (0%) 3 (1.4%) 
Thrombocytopenia 1 (0.4%) 0 (0%) 
Gastrointestinal   
Nausea, Anorexia, Constipation 0 (0%) 0 (0%) 
Cardiac   
Congestive heart failure 0 (0%) 1 (0.5%) 
Cardiomyopathy 1 (0.4%) 1 (0.5%) 
Infectious   
Infection, Fever 0 (0%) 0 (0%) 
Miscellaneous   
Asthenia 3 (1.3%) 4 (1.9%) 
Headache, Pain 0 (0%) 0 (0%) 
BV ... Bevacizumab; CAP ... Capecitabine; 
 
 
In this multi-centre open-label trial [24, 33], 462 women with metastatic 
breast cancer previously treated with both an anthracycline and a taxane 
therapy (no more than 2 regimens) received either capecitabine alone or in 
combination with bevacizumab. HER2 status was not an inclusion criterion, 
thus 20% and 26% were HER2-positive in the control group and in the 
intervention group respectively. 230 women were randomly assigned to the 
control group with capecitabine monotherapy (an orally-administered pro-
drug of 5-flourouracil), and 232 women were allocated to the intervention 
arm to additionally receive bevacizumab (a monoclonal antibody to vascular 
endothelial growth factor). To be included, patients had to have an Eastern 
Cooperative Oncology Group (ECOG) performance status of 0-1 and a life 
expectancy of more than 3 months. Subjects with known HER2-positive 
status had to have a disease progression following trastuzumab therapy. 
Among the included patients a minority (about 15%) did not receive their 
prior anthracycline and taxane therapy for metastatic disease but as an 
adjuvant chemotherapy and had relapsed within 12 months. However, 93 
patients (i.e. 20%) treated did not fulfil the inclusion criteria. Even though 
the authors mentioned that this fact did not alter outcomes, no information 
is provided on how these patients were distributed between the two 
treatment groups and the results are also missing.  
The primary end point PFS did not show favourable results for the 
intervention group on combined therapy (capecitabine + bevacizumab 4.86 
months vs. capecitabine alone 4.17 months; HR 0.98 (95% CI 0.77-1.25; 
p=0.857)). In contrast, the secondary end point ORR (as assessed by an 
independent review facility) was significantly improved with the addition of 
bevacizumab (19.8% vs. 9.1%; p =0.001), but did not translate into an 
improved PFS, because only a minority of subjects showed tumour 
responses and responses in the intervention arm were relatively short-lived. 
Data on complete responses (CR) and partial responses (PR) were not 
reported. 
At data cutoff 38% of all patients had died. Median overall survival was 
similar in the two treatment arms. The median duration of survival (DoS) 
study population and 
inclusion criteria 
treatment group: 
capecitabine + 
bevacizumab 
control group: 
capecitabine 
 
 
 
 
 
20% did not fulfil 
inclusion criteria 
similar PFS 
 
beneficial ORR, but no 
data on CRs 
similar overall survival 
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was 15.1 months for women in the intervention group and 14.5 months for 
patients in the control arm. 
The secondary endpoint QoL was assessed for a subset of women who have 
had at least one subsequent QoL assessment after baseline (176 controls, 194 
combination therapy subjects). It was measured by the Trial Outcome Index 
(TOI; the sum of the physical well-being, functional well-being, and breast 
cancer–specific questions in the Functional Assessment Of Cancer 
Treatment - Breast questionnaire (FACT-B)). The time to deterioration in 
QoL (TDQ) did not differ between treatment groups (median capecitabine 
+ bevacizumab 2.92 months vs. capecitabine alone 2.86 months; p=0.633). 
The incidence of severe adverse events (SAEs) and AEs leading to study 
discontinuation were similar between the treatment arms; more detailled 
data are not reported. These data have to be interpreted with caution due to 
the before mentioned fact that 20% of patients treated did not fulfil study 
entry criteria, but it remains unclear to which group these patients were 
allocated to. For example, 27 patients had received prior therapy within 21 
days, 19 have had more than two regimens for metastatic disease and 10 had 
involvement of the central nervous system, factors that potentially influence 
the occurrence of AEs.  
Capecitabine-related AEs occurred slightly more often in the combined 
intervention arm, although bevacizumab did not significantly increase the 
capecitabine-related toxicity. There may have been a small increase in hand-
foot syndrome in the intervention group (grade 2: 42.4% vs. 35.8%; grade 3: 
27.5% vs. 24.2%). Other common capecitabine-related AEs were diarrhoea 
(capecitabine + bevacizumab vs. capecitabine alone: grade 2: 16.2% vs. 
15.8%; grade 3: 11.8% vs. 10.7%) and stomatitis (capecitabine + 
bevacizumab vs. capecitabine alone: grade 2: 7.0% vs. 5.1%; grade 3: 1.7% vs. 
0%; grade 4: 0% vs. 0.5%). 29 patients (12.6%) in the capecitabine group and 
28 (12.2%) in the combination group discontinued capecitabine treatment 
due to toxicity. 
Among the bevacizumab-related AEs hypertension, proteinuria and 
bleedings were the most common. Concerning hypertension  most events in 
the intervention group were grade 3 AEs (capecitabine + bevacizumab vs. 
capecitabine alone: grade 1: 3.9% vs. 1.9%; grade 2: 1.7% vs. 0%; grade 3: 
17.9% vs. 0.5%). 4 (1.7%) patients discontinued bevacizumab because of 
hypertension. Most occurrences of proteinuria and bleedings in the 
combination group were AEs of lower grade: proteinuria (capecitabine + 
bevacizumab vs. capecitabine alone: grade 1: 18.3% vs. 6.5%; grade 2: 3.1% 
vs. 0.9%; grade 3: 0.9% vs. 0%) and bleedings (capecitabine + bevacizumab 
vs. capecitabine alone: grade 1: 26.2% vs. 8.8%; grade 2: 2.2% vs. 1.9%; grade 
3: 0.4% vs. 0.5%). There were no grade 4 haemorrhages reported. 2 (0.9%) 
women stopped bevacizumab treatment because of grade 3 proteinuria.  
Over all, more patients in the intervention arm had congestive heart failure 
or cardiomyopathy of grade 3 or 4 (capecitabine + bevacizumab vs. 
capecitabine alone: grade 3: 2.6% vs. 0%; grade 4: 0.4% vs. 0.9%). 5 (2.2%) 
patients were discontinued from bevacizumab due to grade 3 or 4 cardiac 
events. 
Adverse events of grade 2 which affected more then 10% of patients in at 
least one treatment arm were nausea, anorexia, infections, asthenia, 
headache and pain. Besides, the most common events (in more than 2% of 
the patients) were asthenia, thrombotic events, pain, nausea, leukopenia and 
anorexia, all of them grade 3 (for details see Table 4).  
no difference in quality 
of life 
SAEs: no difference 
capecitabine-related 
toxicity not significantly 
affected 
hand-foot syndrome 
may be increased 
bevacizumab-related 
toxicity 
more hypertensive events 
more proteinuria and 
bleedings, mainly grade 1 
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The investigators of the study concluded that the safety profile in this 
heavily pretreated patient population was acceptable. Although the addition 
of bevacizumab to capecitabine produced a significant improvement in 
objective response rate, this did not increase progression-free survival. 
6.2 Efficacy and safety - further studies 
All phase II studies included HER2-negative patients or HER2-positive pa-
tients, previously treated with trastuzumab. 
Results of a single arm phase II study were published in 2008 by Burstein et 
al. [25]. 56 women, who had received one or two prior chemotherapy regi-
mens for metastatic breast cancer, were treated with bevacizumab and vi-
norelbine. Patients received bevacizumab 10 mg/kg every 2 weeks, and vi-
norelbine each week, until tumour progression or prohibitive toxicity. The 
ORR was 34% (95% CI: 22-48%) and median time to progression (TTP) was 
5.5 months. The most common AEs were uncomplicated neutropenia (30%), 
nasal congestion/epistaxis (21%) and hypertension (16%). Three patients 
had impaired wound healing following surgical procedures. 
A phase I/II single arm trial of bevacizumab included 75 previously treated 
metastatic breast cancer patients [26]. They were treated with escalating 
doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered in-
travenously every other week. The ORR was 9.3% (confirmed response rate: 
6.7%). The median duration of confirmed response was 5.5 months (range, 
2.3 to 13.7 months). At the final tumour assessment (day 154), 16% had sta-
ble disease or an ongoing response. Four patients discontinued study treat-
ment because of an AE. Hypertension was reported as an AE in 22%. 
In Dickler et al. [27] 38 patients with metastatic BC were enrolled and treat-
ed with erlotinib (150 mg daily) and bevacizumab (15 mg/kg every 3 weeks). 
All patients had one to two prior chemotherapy regimens for metastatic dis-
ease. Median TTP was 11 weeks (95% CI: 8-18 weeks). One patient achieved 
a PR for 52+ months. Fifteen patients had stable disease at first evaluation 
at 9 weeks and 4 of these patients had stable disease beyond 26 weeks. The 
most common AEs were diarrhoea of any grade (84%), grade 1 or 2 skin rash 
(76%) and hypertension (18%). 
bevacizumab + 
vinorelbine  
median TTP was 5.5 
months 
different doses of 
bevacizumab 
hypertension as most 
common AE 
bevacizumab + erlotinib 
median TTP was 11 
weeks 
84% diarrhoea of any 
grade 
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Another single arm phase II trial [28] investigated bevacizumab in combina-
tion with metronomic chemotherapy in 24 patients with anthracycline- and 
taxane-refractory breast cancer. 50 mg cyclophosphamide were given daily, 
methotrexate 1 mg/kg every 14 days, and bevacizumab 10 mg/kg every 14 
days. Trastuzumab was added in HER2-overexpressing tumours. After a 
median follow-up of 7.7 months CR was 0% and PR 31.8% (95% CI: 13.9- 
54.9%). Stable disease ≥ 24 weeks was 31.8% (95% CI: 13.9-54.9%). Median 
PFS was 7.5 months and OS was 13.6 months. HER2-overexpressing or high 
proliferative-index tumours had better 6-month PFS (75% vs. 34% in 
HER2-negative tumours, p = 0.043; 67% vs. 0% in Ki-67 ≥ 20% tumours, p 
= 0.015). Adverse effects were mild. 
In 2 further phase II trials bevacizumab in combination with chemotherapy 
was evaluated as salvage therapy for women with metastatic BC and at least 
1 prior chemotherapy regimens. In the first study [29] patients received vi-
norelbine (50 mg 3 times a week) and bevacizumab (10 mg/kg every 14 
days). The therapy was continued until disease progression or the appear-
ance of unacceptable toxicity. The primary endpoint was ORR. The median 
age of the 13 evaluable patients was 67 (range 41-80) and they were treated 
for a median of 5 cycles (range 1-9). The ORR was 7.7% with PR in one pa-
tient and stable disease in 7 patients. The TTP was 4.5 months. Significant 
toxicities were uncommon, with grade 3 toxicities occurring in one of the pa-
tients (neutropenia). The study was closed early due to lack of efficacy.  
The second trial [30] investigated paclitaxel (90mg/m2 on days 1, 8 and 15) 
in combination with bevacizumab (10mg/kg on days 1 and 5) in pre-treated 
women with metastatic BC. It was second-line chemotherapy for 30% and 
third-line or more for 70% of patients. A total of 40 patients with median age 
61 years (range 32-80) were enrolled. Two patients (5%) achieved CR and 10 
patients (25%) PR. The ORR was 30% (95% CI: 15.8 - 44.2). After a median 
follow-up of 20.6 months, the median TTP was 4.8 months (95% CI: 1.7-7.8), 
the median survival 13.0 months (95% CI: 10.3 - 15.7), and the probability of 
1-year survival 55.5%. Main grade 3-4 AEs were neutropenia (43%), asthenia 
(10%) and febrile neutropenia (5%). There was one toxic death due to sepsis.  
7 Estimated costs 
In Austria, the manufacturer price for one 4ml-vial of Avastin® is € 414.05, 
and for one 16ml vial € 1,421.90, containing 25mg/ml bevacizumab [34]. The 
recommended dosing regimen for the treatment of metastatic breast cancer 
is 10 mg/kg body weight given once every 2 weeks. Assuming a mean body 
weight of 70 kg a dose of 700 mg bevacizumab (10 mg/kg) should be admin-
istered. Therefore, one 16ml vial and three 4ml vials are required, resulting 
in costs of € 2,664.05 for each injection and, accordingly, in monthly costs of 
about € 5,330.-. In the RIBBON-2 trial the median number of doses of 
bevacizumab received was nine, adding up to total costs of about € 24,000.- 
for a full course therapy. 
bevacizumab + 
metronomic 
chemotherapy 
31.8% PR after median 
7.7 months 
 
 
 
 
bevacizumab + 
vinorelbine as salvage 
therapy 
ORR was 7.7% 
closed early due to lack 
of efficacy 
bevacizumab + 
paclitaxel as salvage 
therapy 
median TTP was 4.8 
months 
1-year survival 55.5% 
monthly treatment 
costs € 5,330.- 
 
 
€ 24,000.- for treatment 
per person 
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8 On-going research 
A search in the databases ClinicalTrials.gov and cinicaltrialsregister.eu 
yielded 2 on-going phase III trials investigating bevacizumab as second-line 
therapy for patients with metastatic breast cancer: 
 NCT00929240 (EudraCT 2008-006872-31): Bevacizumab and capecit-
abine as maintenance therapy in HER2-negative metastatic BC pa-
tients. The completion of the study is planned for September 2013. 
 NCT01250379 (EudraCT 2010-020998-16): Bevacizumab in combina-
tion with chemotherapy in patients with breast cancer progressing af-
ter first-line therapy with Avastin® and chemotherapy. The estimated 
study completion date is December 2014. 
In addition, 3 on-going phase II controlled trials and 3 phase II single-arm 
trials for bevacizumab as second-line therapy for metastatic BC and more 
than 70 on-going Phase III or IV studies evaluating bevacizumab in a broad 
variety of indications such as colorectal cancer, non-small cell lung cancer, 
macular degeneration or breast cancer were found. 
9 Commentary  
Bevacizumab in combination with chemotherapy has currently no market 
approval as a second-line therapy for metastatic BC, neither in the US nor in 
Europe, but it is approved in combination with chemotherapy by the EMA 
and FDA as first-line therapy for various types of advanced or metastatic 
cancers like colon carcinoma, non-small cell lung cancer, renal cancer and 
for first-line therapy of metastatic breast cancer. For the latter one, differ-
ences existed for the licensed indications since the FDA had limited Avas-
tin® to HER2-negative patients only, whereas the EMA did not restrict 
bevacizumab to HER2-negative patients; its usage, however, was restricted 
to combination with paclitaxel only [4]. Furthermore, the FDA withdrew 
approval for Avastin®  first-line therapy for BC due to lack of clinical benefit 
based on the results of the AVADO trial and the RIBBON-1 trial in 2011 [7]. 
After accelerated approval had been granted in 2008, updated data of these 
two trials did not confirm an anticipated 5.5 months increase in median 
PFS, as suggested by initial study results [7]. According to the FDA the tox-
icity profile was not tolerable for a drug, for which the clinical benefit has 
not been shown [7]. 
For other lines of therapy, two phase III trials assessing bevacizumab in 
combination with chemotherapy in previously treated patients with metas-
tatic BC were identified [23, 24, 31-33]. 
2 phase III studies for 
second-line therapy of 
metastatic BC 
6 phase II studies for 
second-line therapy of 
metastatic BC 
plenty phase III studies 
for other indications 
BV currently not 
approved for second-
line treatment of 
metastatic BC 
differences in licensed 
indications between 
EMA and FDA 
FDA withdrew market 
application for first-line 
therapy in HER2-
negative patients in 2011 
two phase III trials for 
other lines of therapy 
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Miller et al. [24], focused on heavily pre-treated women (who already had re-
ceived both anthracycline and taxane regimens (up to 2)). HER status was 
not an inclusion criterion and therefore HER2-negative as well as HER2-
positive patients were enrolled. When compared to capecitabine monother-
apy, the addition of bevacizumab did not improve the primary endpoint PFS 
or any other reported outcome except ORR. Although various subgroup 
analyses on the impact of potential prognostic factors had been planned, no 
results were reported. 
The second phase III trial (RIBBON-2) evaluated second-line bevacizumab 
in combination with different chemotherapeutic regimens in women with 
metastatic HER2-negative BC. For the primary endpoint, PFS, an absolute 
gain of 2.1 months was shown for patients treated with bevacizumab in com-
parison to those with chemotherapy only. The risk of progression or death 
was reduced by 22% for bevacizumab + chemotherapy, yielding a statisti-
cally significant improvement in comparison to placebo + chemotherapy. 
Yet, for all other endpoints (ORR, OS, 1 year survival) there were no differ-
ences between the groups. Among others, subgroup analyses regarding tri-
ple-negative BC and type of chemotherapy regimen were performed (n 
=159), showing improvements in PFS for women with triple-negative BC 
and for patients who had received taxanes as chemotherapy.  
The trials showed different results for the primary endpoint PFS.  Only in 
the RIBBON-2 trial, bevacizumab + chemotherapy resulted in a statistically 
significant prolongation of the PFS.  One reason for that may be the differ-
ent study populations. Overall, women in the trial by Miller et al. were more 
heavily pre-treated, had more heterogeneous disease (e. g. HER2-status) and 
poorer prognoses. At study entry, about 40% of the patients had at least 2 
prior chemotherapies for metastatic BC, while in the RIBBON-2 trial all 
participants had received only one prior chemotherapy. The different PFS 
results may also be caused by the cytotoxic agents used for the combination 
with bevacizumab. Results from subgroup analyses in the RIBBON-2 trial 
suggest that the combination with taxanes was primarily responsible for the 
favourable effects on PFS. More than 40% of the women in the RIBBON-2 
trial received a taxane regimen and just 20% capecitabine, which was the on-
ly cytotoxic agent used in the Miller trial. 
In terms of adverse events, Miller et al. found similar results between the 
two treatment groups in heavily pre-treated patients, but as already men-
tioned earlier, about 20% of patients did not fulfil the initial eligibility crite-
ria and it remains unclear how these patients were distributed between the 
two arms, potentially influencing these results. In the RIBBON-2 study, no 
difference in treatment-emergent deaths was observed, but selected AEs≥3 
(I 35% vs C 23%) and SAEs (I 25% vs C 18%) occurred more often in the 
combination arm than in the chemotherapy only arm. Consequently, AEs 
leading to treatment discontinuation were more frequent in the bevacizu-
mab group (I 13% vs C 7%).  
Besides efficacy outcomes, therapy for metastatic BC aims at improving QoL 
which was not addressed adequately in both trials. Until now, the only result 
reported by Miller et al. [24] was the time to deterioration in QoL with no 
difference between the groups. A separate report with more detailled 
information on QoL announced by the authors has not been published yet.  
QoL has not at all been addressed in the RIBBON-2 trial. 
no significant PFS 
improvement in study 
with heavily pre-treated 
women 
better results for ORR in 
bevacizumab 
combination arm 
+2.1 months in median 
PFS 
no improvements in 
other outcomes 
PFS improved  in TNBC 
and women treated 
with taxanes 
different PFS results 
possibly depend on 
study population or 
cytotoxic agents 
AE comparable in 
heavily pre-treated 
patients (Miller et al.), 
more frequent in 
RIBBON-2 
 
inadequate data on QoL 
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In summary, an increase in PFS by 2.1 months, a higher incidence in AEs 
and the considerable costs of bevacizumab therapy [35], challenge even off-
label use for the second-line therapy of HER2-negative metastatic breast 
cancer. According to the British “National Institute for Health and Clinical 
Excellence” (NICE), a planned appraisal of bevacizumab for this indication 
[36] was suspended in November 2011, because NICE was informed by the 
manufacturer that application for a centralised marketing authorisation was 
not planned.  
However, considering the communication between the manufacturer and the 
FDA [7], it might be possible that the manufacturer will apply for approval 
of more specific indications, e. g. for a subset of patients like women with 
triple negative BC, since the RIBBON-2 trial [31] reported a trend towards 
improved overall survival in these patients. In addition, several trials 
investigating bevacizumab in triple negative BC patients are registered at 
ClinicalTrials.gov. Nevertheless, according to the FDA the available 
evidence does also not demonstrate that Avastin® would confer a meaningful 
clinical benefit in the light of its risks in this subgroup. 
Therefore, further research should not only investigate the clinical safety 
and efficacy of bevacizumab, preferably in terms of OS, but should also 
clarify if biological markers have to be considered prior to treatment 
administration. As therapy for metastatic BC usually aims at symptom 
palliation, especially more information on patient relevant outcomes like 
QoL is needed.  
NICE: second-line 
appraisal suspended, 
because centralised 
market application not 
planned by 
manufacturer 
 
applications for 
approval in subsets of 
patients conceivable 
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